AstraZeneca shares drop by 6% after halting COVID-19 vaccine trials
Category: #headlines  | By Nikita Chaurasia  | Date: 2020-09-10 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

AstraZeneca shares drop by 6% after halting COVID-19 vaccine trials

AstraZeneca plc, a British-Swedish pharmaceutical & biopharmaceutical leader, has recently made it to the headlines for witnessing a 6% plunge in shares after voluntarily halting its late-stage trial for a potential COVID-19 vaccine.

Sources close to the matter cited that the company had put the trial on hold as mean of caution after a study participant in the United Kingdom was experiencing adverse reactions of the potential vaccine.

For the uninitiated, AstraZeneca had developed a vaccine called AZD1222 which was engineered to use a modified adenovirus that carries certain genetic materials of the coronavirus.

The vaccine uses the technology that was employed for developing an experimental Ebola vaccine that was catered to people in the Democratic Republic of Congo in the year 2019, sources claimed.

It is to be noted that the U.S. government struck a deal with AstraZeneca and funded over USD 1.2 billion for the development of a COVID-19 vaccine as well as to secure at least 300 doses for the U.S. population.

Researchers involved in the trials claimed that the AZD1222 vaccine showed no adverse effects apart from headache, fatigues, muscle pain, and fever. The nature of the case leading to the suspension of the trials is not known, however, the volunteer is expected to recover soon.

Evidently, AstraZeneca had commenced the trial round towards the end of last month and is one of three companies to initiate late-stage testing for a potential vaccine. The other two companies are Massachusetts-based biotech company Moderna and Pfizer Inc., a renowned pharmaceutical corporation.

In other news, the Russian Health Ministry has reportedly initiated the distribution of the first batch of the COVID-19 vaccine Sputnik V, which is developed by Gamaleya National Research Center of Epidemiology & Microbiology.

Source credits: https://www.cnbc.com/2020/09/08/astrazeneca-shares-fall-after-coronavirus-vaccine-study-is-put-on-hold.html

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Arm Holdings achieves $54.5 Billion Valuation in successful U.S. IPO

Arm Holdings achieves $54.5 Billion Valuation in successful U.S. IPO

By Nikita Chaurasia

Arm Holdings Plc, the renowned chip designer, has reportedly secured a valuation of $54.5 billion through its U.S. initial public offering (IPO) on Wednesday. This milestone comes seven years after its acquisition by SoftBank Group Corp for $32 billi...

JSW Steel to increase its capacity by double in the next 3 years

JSW Steel to increase its capacity by double in the next 3 years

By Nikita Chaurasia

According to Chairman Sajjan Jindal, JSW Steel has set a target to increase its capacity to 50 million tonnes within the next three years. Speaking at an event organized by the Bombay Chartered Accountants Society, Jindal also mentioned the company&#...

KLM unveils World Business Class Seats for optimal comfort & privacy

KLM unveils World Business Class Seats for optimal comfort & privacy

By Nikita Chaurasia

KLM Royal Dutch Airlines has reportedly unveiled its latest World Business Class seats, designed to provide enhanced comfort and privacy. The World Business Class seats feature a sliding door, ensuring a greater sense of personal space. Additional...